The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    November 2019

  • Pages
    310

  • View Count
    4852

Example Insights

Antibody Drug Conjugates Context Antibody Drug Conjugates Companies Antibody Drug Conjugates Market
Antibody Drug Conjugates Competition Antibody Drug Conjugates Partners Antibody Drug Conjugates Patents
Antibody Drug Conjugates Collaborations Antibody Drug Conjugates Deals Antibody Drug Conjugates Market Forecast

 

Overview

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 200 in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells / pathogens, consequently, addressing most of the concerns related to off target toxicities. In this context, the role of the linker molecule and the conjugation technology used is pivotal. In fact, conjugation chemistry has been shown to be directly related to the drug to antibody ratio (DAR) achieved, and thereby, governs the pharmacokinetic and pharmacodynamic properties of an ADC. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation. 

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. Over time, the evolution of recombinant DNA technology and advances in conjugation techniques, have enabled researchers to significantly improve the bioconjugation process. In fact, next generation conjugation technologies use artificially integrated lysine / cysteine residues in order to improve the DAR of the resulting conjugate. Additionally, there are multiple technologies that claim to offer site-specific conjugation. There are a number of other noteworthy developments in the conjugation technologies domain, which include a variety of competent platforms based on various ligation, disulfide rebridging and protein remodeling approaches. Further, linker technologies have also evolved substantially, and there is vast array of linkers, including cleavable and non-cleavable variants, which are designed to govern drug release mechanism of conjugated therapeutic molecules.

It is worth highlighting that multiple licensing agreements / collaborations have been inked between drug developers and technology providers to advance the development of pipeline ADC candidates. Over the years, a number of start-ups / small companies, offering novel conjugation technologies, more potent cytotoxins / warheads and advanced linker chemistries, have been established to facilitate development of ADCs and other conjugated pharmaceuticals. We anticipate this niche and upcoming market to witness substantial growth over the coming years. 

Scope of the Report

The “Antibody Drug Conjugates: Linker and Conjugation Technologies Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities within the ADC linker and conjugation technologies market, over the next 10-12 years. In addition to other elements, the report includes:

  • An overview of the overall landscape of ADC linker and conjugation technologies, featuring  an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.
  • Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.
  • A list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company’s ADC pipeline strength, likely partners and development status of the ADC molecules.
  • A detailed competitiveness analysis of ADC linker and conjugation technologies, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as ADC generation, type of linker, DAR of the ADCs developed using the technology, availability of patent protection, number of deals signed for a particular technology (2016-2019),  and popularity of the technology (in terms of the number of ADCs developed using the technology). 
  • An in-depth analysis of the various patents that have been filed / granted related to linker / conjugation technologies till August 2019, taking into consideration parameters, such as patent type, publication year, issuing authority / patent offices involved, CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for ADC linker and conjugation technologies. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across the [A] type of linker (cleavable, non-cleavable and both), [B] type of conjugation (chemical, enzymatic and others) [C] key technologies, and [D] key geographical regions (North America, Europe and Asia Pacific/ rest of the world). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following industry stakeholders:

  • Mary Chaohong Hu (Chief Executive Officer, Shanghai Miracogen)
  • Wouter Verhoeven (Chief Business Officer, NBE Therapeutics)
  • Floris van Delft (Chief Scientific Officer, Synaffix)
  • Jan Modregger (Head of Research & Development, EUCODIS Bioscience)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the ADC linker and conjugation technologies service providers market and its evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to ADCs, featuring details related to their various components and advantages over traditional targeted therapies. The chapter emphasizes on the role of linker and conjugation technologies in development of ADCs. Additionally, it provides an overview of the different types of linkers and conjugation technologies, highlighting their key specifications. It also features a brief discussion on anticipated future trends and how this field of research is likely to evolve over the coming decade.

Chapter 4 provides a detailed overview of the overall landscape of ADC linker and conjugation technology providers. It features an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.

Chapter 5 provides detailed profiles of the leading stakeholders in this field. Each profile includes a brief overview of the company, its financial performance (if available), information on its technology portfolio, recent developments and an informed future outlook.

Chapter 6 features an in-depth analysis and discussion on the various collaborations and partnerships inked between the players in this market that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.

Chapter 7 presents a list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company’s ADC pipeline strength, likely partners and development status of the ADC molecules.

Chapter 8 presents a competitiveness analysis of the technologies based on supplier power of the developers and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 9 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to linker and conjugation technologies till August 2019. The analysis also highlights the key trends associated with these patents, across patent type, publication year, issuing authority / patent offices involved, CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 10 provides a review of the novel ADC conjugation technologies, highlighting the evolution of the technologies and the various approaches that have been adopted across different generations of ADCs. In addition, it presents a review of the existing competition between different type of conjugation approaches that are available / under development.

Chapter 11 presents an insightful market forecast analysis, highlighting likely growth of ADC linkers and conjugation technologies market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future. We have provided inputs on the likely distribution of the opportunity by type of linker (cleavable and non-cleavable), type of conjugation (chemical, enzymatic and others), key technologies and key geographical regions (North America, Europe, Asia Pacific and rest of the world).
 
Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Mary Chaohong Hu (Chief Executive Officer, Shanghai Miracogen), Wouter Verhoeven (Chief Business Officer, NBE Therapeutics), Floris van Delft (Chief Scientific Officer, Synaffix) and Jan Modregger (Head of Research & Development, EUCODIS Bioscience).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of this segment of the ADC linker and conjugation technologies.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE
1.1.  Scope of the Report
1.2.  Research Methodology
1.3.  Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibody-based Therapeutics

3.3 Antibody Drug Conjugates (ADCs)
3.3.1 Components of ADCs
3.3.1.1 Antibody
3.3.1.2 Cytotoxin
3.3.1.3 Linker

3.4. Advantages of ADCs over Traditional Pharmacological Interventions
 
3.5. ADC Linker Technologies
3.5.1. Non-cleavable Linkers
3.5.2. Cleavable Linkers

3.6. ADC Conjugation Technologies
3.6.1. Chemical Conjugation
3.6.2. Enzymatic Conjugation
 
3.7. Future Perspectives
 
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
 
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by ADC Generation
4.2.3. Analysis by Type of Linker
4.2.4. Analysis by Type of Conjugation
4.2.5. Analysis by Site Specificity
4.2.6. Analysis by Drug to Antibody Ratio
4.2.7. Analysis by Patent Availability
4.2.8. Analysis by Licensing Activity
 
4.3. ADC Linker and Conjugation Technologies: Developer Landscape
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size 
4.3.3 Analysis by Geographical Location
4.3.4 Leading ADC Developers: Analysis by Number of Technologies
4.3.5 Grid Representation: Analysis by ADC Generation, Type of Linker, Company Size, and Geographical Location
4.3.6 World Map Representation: Analysis by Geography
 
4.4 ADC Linker and Conjugation Technologies: Service Providers
 
5. COMPANY PROFILES
5.1 Chapter Overview
5.2 Key Players in North America
5.2.1 Ambrx
5.2.1.1 Company Overview
5.2.1.2 Technology Overview
5.2.1.3 Recent Developments and Future outlook
 
5.2.2 Catalent Biologics
5.2.2.1 Company Overview
5.2.2.2 Financial Information
5.2.2.3 Technology Overview
5.2.2.4 Recent Developments and Future outlook
 
5.2.3 Immunomedics
5.2.3.1 Company Overview
5.2.3.2 Financial Information
5.2.3.3 Technology Overview
5.2.3.4 Recent Developments and Future outlook
 
5.2.4 Mersana Therapeutics
5.2.4.1 Company Overview
5.2.4.2 Financial Information
5.2.4.3 Technology Overview
5.2.4.4 Recent Developments and Future outlook
 
5.2.5 Seattle Genetics
5.2.5.1 Company Overview
5.2.5.2 Financial Information
5.2.5.3 Technology Overview
5.2.5.4 Recent Developments and Future outlook
 
5.2.6 Sutro Biopharma
5.2.6.1 Company Overview
5.2.6.2 Financial Information
5.2.6.3 Technology Overview
5.2.6.4 Recent Developments and Future outlook
 
5.3 Key Players in Europe and Asia
 
5.3.1 Iksuda Therapeutics
5.3.1.1 Company Overview
5.3.1.2 Technology Overview
5.3.1.3 Recent Developments and Future outlook
 
5.3.2 LegoChem Biosciences
5.3.2.1 Company Overview
5.3.2.2 Technology Overview
5.3.2.3 Recent Developments and Future outlook
 
5.3.3 LinXis
5.3.3.1 Company Overview
5.3.3.2 Technology Overview
5.3.3.3 Recent Developments and Future outlook
 
5.3.4 NBE Therapeutics
5.3.4.1 Company Overview
5.3.4.2 Technology Overview
5.3.4.3 Recent Developments and Future outlook
 
6. PARTNERSHIPS AND COLLABORATIONS
6.1 Chapter Overview
6.2 Partnership Models
 
6.3 List of Partnerships and Collaborations
6.3.1 Analysis by Year of Partnership
6.3.2 Analysis by Type of Partnership
6.3.3 Analysis by Type of Linker
6.3.4 Analysis by Type of Conjugation
6.3.5 Analysis by Year of Partnership and Type of Partner
6.3.6 Analysis by Type of Partnership and Type of Partner 
6.3.7 Most Active Players: Analysis by Number of Partnerships
6.3.8 Most Popular Technologies: Analysis by Number of Partnerships
6.3.9 Regional Analysis
6.3.10 Intercontinental and Intracontinental Agreements
 
7. LIKELY PARTNERS ANALYSIS 
7.1 Chapter Overview
7.2 Scope and Methodology
7.3 ADC Linker and Conjugation Technologies: Potential Strategic Partners in North America
7.3.1 Most Likely Partners
7.3.2 Likely Partners
7.3.3 Less Likely Partners
 
7.4 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Europe
7.4.1 Most Likely Partners
7.4.2 Likely Partners
7.4.3 Less Likely Partners
 
7.5 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Asia-Pacific
7.5.1 Most Likely Partners
7.5.2 Likely Partners
7.5.3 Less Likely Partners
 
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1 Chapter Overview
8.2 Methodology
8.3 Assumptions and Key Parameters
8.4 Technology Competitiveness Analysis
8.4.1 Technologies Developed by Companies based in North America 
8.4.2 Technologies Developed by Companies based in Europe 
8.4.3 Technologies Developed by Companies based in Asia Pacific / RoW
 
9. PATENT ANALYSIS
9.1 Chapter Overview
9.2 Scope and Methodology
9.3 ADC Linker and Conjugation Technologies: Patent Portfolio 
9.3.1 Analysis by Publication Year
9.3.2 Analysis by Issuing Authority / Patent Offices Involved 
9.3.3 Analysis by CPC Symbols 
9.3.4 Emerging Focus Areas
9.3.5 Analysis by Type of Company / Organization
9.3.6 Leading Assignees: Analysis by Number of Patents
 
9.4 ADC Linker and Conjugation Technologies: Patent Benchmarking Analysis
9.4.1 Analysis by Patent Characteristics
9.5 ADC Linker and Conjugation Technologies: Patent Valuation Analysis
 
10. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
10.1 Chapter Overview
10.2 First Generation ADC Technologies
 
10.3 Second Generation ADC Technologies
10.3.1  Cysteine and Selenocysteine Engineering
10.3.2  Unnatural Amino Acid Engineering
10.3.3  Amino-Terminal Serine Engineering
  
10.4 Third Generation ADC Technologies
10.4.1 Enzyme-Assisted Ligation Approaches
10.4.2  Glycan Remodeling Approaches
10.4.3  Ligation at Fab Nucleotide-Binding Site
10.4.4  Cysteine Rebridging
10.4.5  Avoiding or Limiting Retro-Michael Drug Deconjugation
  
10.5 Evolutionary Analysis
 
11. MARKET SIZING AND FORECAST
11.1 Chapter Overview
11.2 Forecast Methodology and Key Assumptions
11.3 Global ADC Linker and Conjugation Technologies Market, 2019-2030
11.4 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030
11.5 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030
11.6 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030
 
11.7 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030
11.7.1 ADC Linker and Conjugation Technologies Market in North America, 2019-2030
11.7.1.1 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030
11.7.1.2 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030
11.7.1.3 ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030
 
11.7.2 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030
11.7.2.1 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030
11.7.2.2 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030
11.7.2.3 ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030
 
11.7.3 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030
11.7.3.1 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030
11.7.3.2 ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030
11.7.3.3 ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030
 
12. EXECUTIVE INSIGHTS
12.1 Chapter Overview
12.2 Miracogen
12.2.1  Company Snapshot
12.2.2  Interview Transcript: Mary Hu, Chief Executive Officer 
 
12.3 NBE Therapeutics
12.3.1  Company Snapshot
12.3.2  Interview Transcript: Wouter Verhoeven, Chief Business Officer
 
12.4 Synaffix
12.4.1  Company Snapshot
12.4.2  Interview Transcript: Floris van Delft, Chief Scientific Officer 
 
12.5 EUCODIS Bioscience
12.5.1  Company Snapshot
12.5.2  Interview Transcript: Jan Modregger, Head of Research & Development
 
13. CONCLUDING REMARKS
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Components of ADCs
Figure 3.2. Types of Linkers
Figure 4.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Figure 4.2. ADC Linker and Conjugation Technologies: Distribution by ADC Generation
Figure 4.3. ADC Linker and Conjugation Technologies: Distribution by Type of Linker
Figure 4.4. ADC Linker and Conjugation Technologies: Distribution by Type of Conjugation
Figure 4.5. ADC Linker and Conjugation Technologies: Distribution by Site Specificity
Figure 4.6. ADC Linker and Conjugation Technologies: Distribution by Drug to Antibody Ratio
Figure 4.7. ADC Linker and Conjugation Technologies: Distribution by Patent Availability
Figure 4.8. ADC Linker and Conjugation Technologies: Distribution by Licensing Activity
Figure 4.9. ADC Linker and Conjugation Technologies: Distribution by Year of Establishment
Figure 4.10. ADC Linker and Conjugation Technologies: Distribution by Company Size
Figure 4.11. ADC Linker and Conjugation Technologies: Distribution by Geographical Location
Figure 4.12. Leading ADC Developers: Distribution by Number of Technologies
Figure 4.13. Grid Representation: Distribution by ADC Generation, Type of Linker, Company Size, and Geographical Location
Figure 4.14. World Map Representation: Analysis by Geography
Figure 5.1. Catalent Biologics: Annual Revenues, 2014- 2019 (USD Million)
Figure 5.2. Immunomedics: Annual Revenues, 2014-2018 (USD Million)
Figure 5.3. Mersana Therapeutics: Annual Revenues, 2015-2019 (H3) (USD Million)
Figure 5.4. Seattle Genetics: Annual Revenues, 2014-2019 (H1) (USD Million)
Figure 5.5. Sutro Biopharma: Annual Revenues, 2016- 2019 (H3) (USD Million)
Figure 6.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2019
Figure 6.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2014-2019. 
Figure 6.4. Partnerships and Collaborations: Distribution by Type of Linker and Type of Partnership
Figure 6.5. Partnerships and Collaborations: Distribution by Type of Conjugation and Type of Partnership
Figure 6.6. Partnerships and Collaborations: Year-wise Trend for Type of Partner
Figure 6.7. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 6.8. Most Active Players: Distribution by Number of Partnerships
Figure 6.9. Most Popular Technologies: Distribution by Number of Partnerships
Figure 6.10. Partnership and Collaborations: Regional Distribution
Figure 6.11. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1. Competitiveness Analysis: Technologies Developed by Companies Based in North America
Figure 8.2. Competitiveness Analysis: Technologies Developed by Companies Based in Europe
Figure 8.3. Competitiveness Analysis: Technologies Developed by Companies Based in Asia Pacific / RoW
Figure 9.1. Patent Analysis: Distribution by Type of Patent
Figure 9.2. Patent Analysis: Cumulative Year-wise Trend, 2016-2019
Figure 9.3. Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 9.4. Patent Analysis: Distribution by CPC Symbols
Figure 9.5. Patent Analysis: Emerging Focus Areas
Figure 9.6. Patent Analysis: Cumulative Distribution by Company / Organization
Figure 9.7. Leading Industry Players in Terms of Number of Patents
Figure 9.8. Leading Non-Industry Players in Terms of Number of Patents
Figure 9.9. Leading Assignees: Distribution by Number of Patents
Figure 9.10. Patent Benchmarking: Roche and AbbVie (based on Patent Characteristics)
Figure 9.11. Patent Benchmarking: Leading Industry Players (based on Patent Characteristics)
Figure 10.1. Evolution of ADC technology Platforms
Figure 10.2. ADC Conjugation Platforms: Technology Landscape
Figure 11.1. Global ADC Linker and Conjugation Technologies Market, 2019-2030 (USD Billion)
Figure 11.2. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.3. Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.4. Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030 (USD Billion)
Figure 11.5. Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030 (USD Billion)
Figure 11.6. ADC Linker and Conjugation Technologies Market in North America, 2019-2030 (USD Billion)
Figure 11.7. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.8. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.9. ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030 (USD Billion)
Figure 11.10. ADC Linker and Conjugation Technologies Market in Europe, 2019-2030 (USD Billion)
Figure 11.11. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.12. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.13. ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030 (USD Billion)
Figure 11.14. ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030 (USD Billion)
Figure 11.15. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030 (USD Billion)
Figure 11.16. ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Figure 11.17. ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030 (USD Billion)

List of Tables

Table 3.1. List of Approved Monoclonal Antibody Therapies
Table 3.2. Commonly Used Cytotoxins in ADC Therapeutics
Table 4.1. ADC Linker and Conjugation Technologies: Overall Market Landscape
Table 4.2 ADC Linker and Conjugation Technologies: Developer Overview
Table 5.1. Leading ADC Linker and Conjugation Technology Companies
Table 5.2. Ambrx: Company Overview
Table 5.3. Ambrx: Drug Portfolio based on ADC Technology
Table 5.4. Ambrx: Recent Developments and Future Outlook
Table 5.5. Catalent Biologics: Company Overview
Table 5.6. Catalent Biologics: Drug Portfolio based on ADC Technology
Table 5.7. Catalent Biologics: Recent Developments and Future Outlook
Table 5.8. Immunomedics: Company Overview
Table 5.9. Immunomedics: Drug Portfolio based on ADC Technology
Table 5.10. Immunomedics: Recent Developments and Future Outlook
Table 5.11. Mersana Therapeutics: Company Overview
Table 5.12. Mersana Therapeutics: Drug Portfolio based on ADC Technology
Table 5.13. Mersana Therapeutics: Recent Developments and Future Outlook
Table 5.14. Seattle Genetics: Company Overview
Table 5.15. Seattle Genetics: Drugs Drug Portfolio based on ADC Technology
Table 5.16. Seattle Genetics: Recent Developments and Future Outlook
Table 5.17. Sutro Biopharma: Company Overview
Table 5.18. Sutro Biopharma: Drug Portfolio based on ADC Technology
Table 5.19. Sutro Biopharma: Recent Developments and Future Outlook
Table 5.20. Iksuda Therapeutics: Company Overview
Table 5.21. Iksuda Therapeutics: Drug Portfolio based on ADC Technology
Table 5.22. Iksuda Therapeutics: Recent Developments and Future Outlook
Table 5.23. LegoChem Biosciences: Company Overview
Table 5.24. LegoChem Biosciences: Drug Portfolio based on ADC Technology
Table 5.25. LegoChem Biosciences: Recent Developments and Future Outlook
Table 5.26. LinXis: Company Overview
Table 5.27. LinXis: Drug Portfolio based on ADC Technology
Table 5.28. LinXis: Recent Developments and Future Outlook
Table 5.29. NBE Therapeutics: Company Overview
Table 5.30. NBE Therapeutics: Drug Portfolio based on ADC Technology
Table 5.31. NBE Therapeutics: Recent Developments and Future Outlook
Table 6.1. ADC Linker and Conjugation Technologies: Partnerships and Collaborations, 2014-2019
Table 7.1. North America: Most Likely Partners 
Table 7.2. North America: Likely Partners 
Table 7.3. North America: Less Likely Partners
Table 7.4. Europe: Most Likely Partners 
Table 7.5. Europe: Likely Partners 
Table 7.6. Europe: Less Likely Partners
Table 7.7. Asia-Pacific: Most Likely Partners 
Table 7.8. Asia-Pacific: Likely Partners 
Table 7.9. Asia-Pacific: Less Likely Partners
Table 9.1. Patent Analysis: CPC Symbol Definitions
Table 9.2. Patent Analysis: Popular CPC Symbols
Table 9.3. Patent Analysis: List of Top CPC Symbols 
Table 9.4. Patent Analysis: List of Leading Assignees
Table 9.5. Patent Analysis: Benchmarking Analysis Summary
Table 9.6. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 10.1. Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 10.2. Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 10.3. Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 10.4. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 10.5. Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 10.6. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 10.7. Third Generation ADC Technologies: Cysteine Rebridging
Table 10.8. Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 12.1. Miracogen: Key Highlights
Table 12.2. NBE Therapeutics: Key Highlights
Table 12.3. Synaffix: Key Highlights
Table 12.4. EUCODIS Bioscience: Key Highlights
Table 14.1     ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Table 14.2     ADC Linker and Conjugation Technologies: Distribution by ADC Generation
Table 14.3     ADC Linker and Conjugation Technologies: Distribution by Type of Linker
Table 14.4     ADC Linker and Conjugation Technologies: Distribution by Type of Conjugation
Table 14.5     ADC Linker and Conjugation Technologies: Distribution by Site Specificity
Table 14.6     ADC Linker and Conjugation Technologies: Distribution by Drug to Antibody Ratio
Table 14.7     ADC Linker and Conjugation Technologies: Distribution by Patent Availability
Table 14.8     ADC Linker and Conjugation Technologies: Distribution by Licensing Activity
Table 14.9     ADC Linker and Conjugation Technologies: Distribution by Year of Establishment
Table 14.10     ADC Linker and Conjugation Technologies: Distribution by Company Size 
Table 14.11     ADC Linker and Conjugation Technologies: Distribution by Geographical Location
Table 14.12     Leading ADC Developers: Distribution by Number of Technologies
Table 14.13     Catalent Biologics: Annual Revenues, 2014- 2019 (USD Million)
Table 14.14     Immunomedics: Annual Revenues, 2014-2018 (USD Million)
Table 14.15     Mersana Therapeutics: Annual Revenues, 2015-2019 (H3) (USD Million)
Table 14.16     Seattle Genetics: Annual Revenues, 2014-2019 (H1) (USD Million)
Table 14.17     Sutro Biopharma: Annual Revenues, 2016- 2019 (H3) (USD Million)
Table 14.18     Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2019
Table 14.19     Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.20     Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 14.21     Partnerships and Collaborations: Distribution by Type of Linker and Type of Partnership
Table 14.22     Partnerships and Collaborations: Distribution by Type of Conjugation and Type of Partnership
Table 14.23     Partnerships and Collaborations: Year-wise Trend for Type of Partner
Table 14.24     Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.25     Most Active Players: Distribution by Number of Partnerships
Table 14.26     Most Popular Technologies: Distribution by Number of Partnerships 
Table 14.27     Partnership and Collaborations: Regional Distribution
Table 14.28     Patent Analysis: Distribution by Type of Patent
Table 14.29     Patent Analysis: Cumulative Year-wise Trend, 2016-2019
Table 14.30     Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved 
Table 14.31     Patent Analysis: Distribution by CPC Symbols
Table 14.32     Patent Analysis: Emerging Focus Areas
Table 14.33     Patent Analysis: Cumulative Distribution by Company / Organization
Table 14.34     Leading Industry Players in Terms of Number of Patents
Table 14.35     Leading Non-Industry Players in Terms of Number of Patents
Table 14.36     Leading Assignees: Distribution by Number of Patents
Table 14.37     Global ADC Linker and Conjugation Technologies Market, 2019-2030 (USD Billion)
Table 14.38     Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.39     Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.40     Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030 (USD Billion)
Table 14.41     Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030 (USD Billion)
Table 14.42     ADC Linker and Conjugation Technologies Market in North America, 2019-2030 (USD Billion)
Table 14.43 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.44 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.45     ADC Linker and Conjugation Technologies Market in North America: Share of Key Technologies, 2019-2030 (USD Billion)
Table 14.46     ADC Linker and Conjugation Technologies Market in Europe, 2019-2030 (USD Billion)
Table 14.47     ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.48     ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.49     ADC Linker and Conjugation Technologies Market in Europe: Share of Key Technologies, 2019-2030 (USD Billion)
Table 14.50     ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030 (USD Billion)
Table 14.51     ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Linker, 2019-2030 (USD Billion)
Table 14.52     ADC Linker and Conjugation Technologies Market in Asia Pacific: Distribution by Type of Conjugation, 2019-2030 (USD Billion)
Table 14.53     ADC Linker and Conjugation Technologies Market in Asia Pacific: Share of Key Technologies, 2019-2030 (USD Billion)

List of Companies

The following companies and organizations are mentioned in the report.

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. AbbVie
  4. AbGenomics
  5. ABL Bio
  6. Abnova
  7. Abzena
  8. ACES Pharma
  9. ADC Biotechnology
  10. ADC Therapeutics
  11. Advanced Proteome Therapeutics
  12. Affinity Life Sciences
  13. AGC Biologics
  14. Agensys
  15. Ajinomoto
  16. Ajinomoto Bio-Pharma Services
  17. Albumedix
  18. Alexion Pharmaceuticals
  19. Allergan
  20. Alpha Cancer Technologies
  21. Alta Partners
  22. Alteogen
  23. Ambrx
  24. Amgen
  25. Angiex
  26. Antikor Biopharma
  27. Araris Biotech
  28. Asana BioSciences
  29. Astellas Pharma
  30. AstraZeneca
  31. Avacta Life Sciences
  32. Bayer
  33. BeiGene
  34. BioAtla
  35. BioCapital
  36. Biogen
  37. BioLegend
  38. BioMed Valley Discoveries
  39. BioOutsource
  40. Bio-Rad Laboratories
  41. Bio-Synthesis
  42. Biotechnique
  43. Biotest
  44. Bio-Thera Solutions
  45. BlinkBio
  46. Bliss Biopharmaceutical
  47. BOC Sciences
  48. Boehringer Ingelheim
  49. Boster Biological Technology
  50. Bristol-Myers Squibb
  51. BSP Pharmaceuticals
  52. Cancer Research UK
  53. Capra Science Antibodies
  54. CARBOGEN AMCIS
  55. Cascadian Therapeutics
  56. Catalent Biologics
  57. Celgene
  58. CellMosaic
  59. Cell Signalling Technology
  60. Cellerant Therapeutics
  61. Celltrion
  62. Centrose
  63. Cerbios-Pharma
  64. Chugai Pharmaceutical
  65. Cisbio
  66. Clovis Oncology
  67. Concortis Biotherapeutics
  68. Corixa
  69. Creative Biolabs
  70. Creative Diagonostics
  71. Creative peptides
  72. CSPC Pharmaceutical Group
  73. CureMeta
  74. Cytogen
  75. CytomX Therapeutics
  76. Daiichi Sankyo
  77. Dalton Pharma Services
  78. Debiopharm Group
  79. Dyax
  80. Eisai
  81. Elan Pharmaceuticals
  82. Eli Lilly
  83. Elusys Therapeutics
  84. EMD Serono
  85. Envigo
  86. Esperance Pharmaceuticals
  87. EUCODIS Bioscience
  88. Eventide Asset Management
  89. Everest Biotech
  90. Everest Medicines
  91. Exelixis
  92. Expedeon
  93. Femtogenix
  94. Fleet Bioprocessing
  95. Formation Biologics
  96. Formosa Laboratories
  97. Fortis Therapeutics
  98. Fosun Pharma
  99. GamaMabs Pharma
  100. Genentech
  101. Genmab
  102. Genovis
  103. GenScript
  104. Genzyme
  105. GlaxoSmithKline
  106. Glycotope
  107. Glythera
  108. Goodwin Biotechnology
  109. GT Biopharma
  110. Hangzhou DAC Biotech
  111. Heidelberg Pharma
  112. Hengrui Medicine
  113. Human Genome Sciences
  114. iBioSource
  115. Iconic Therapeutics
  116. Iksuda Therapeutics
  117. ImClone Systems
  118. ImmunoBiochem
  119. ImmunoGen
  120. Immunomedics
  121. Innate Pharma
  122. Innovate UK
  123. IntoCell
  124. IONTAS
  125. iProgen Biotech
  126. Iterum Therapeutics
  127. Janssen Biotech
  128. Johnson & Johnson
  129. Johnson Matthey
  130. Kairos Therapeutics
  131. KLUS Pharma
  132. Kyowa Hakko Kirin
  133. LakePharma
  134. LegoChem Bioscienses
  135. Leinco Technologies
  136. Leukemia & Lymphoma Society
  137. Levena Biopharma
  138. Life Technologies
  139. Light Chain Bioscience
  140. Lilly Ventures
  141. LinXis
  142. MabPlex
  143. MabSpace Biosciences
  144. MabVax Therapeutics
  145. MacroGenics
  146. Magenta Therapeutics
  147. Maine Biotechnology
  148. MediaPharma
  149. MedImmune
  150. Meditope Biosciences
  151. MedKoo Biosciences
  152. Memorial Sloan Kettering Cancer Center
  153. Menarini Group
  154. Merck
  155. Mersana Therapeutics
  156. Millennium Pharmaceuticals
  157. Mitsubishi Tanabe Pharma
  158. MorphoSys
  159. Morphotek
  160. MuseChem
  161. NanoValent Pharmaceuticals
  162. National Research Council of Canada
  163. NBE-Therapeutics
  164. NeoRx
  165. Nexthera Capital
  166. Nordic Nanovector
  167. Noria Pharmaceuticals
  168. Novartis
  169. NovaTeinBio Novimmune
  170. NovoCodex Biopharmaceuticals
  171. Novozymes
  172. OBI Pharma
  173. OcellO
  174. OGD2 Pharma
  175. Oncolinx
  176. Oncomatryx Biopharma
  177. Oncotec Pharma Produktion
  178. Organon Teknika
  179. OriGene Technologies
  180. Oxford BioTherapeutics
  181. Palatin Technologies
  182. Pfizer
  183. Pharmaron
  184. Philochem
  185. Pierre Fabre
  186. Piramal Pharma Solutions
  187. ProBioGen
  188. Progenics Pharmaceuticals
  189. ProteoGenix
  190. Puma Biotechnology
  191. Rakuten Medical
  192. Recepta Biopharma
  193. Redwood Bioscience
  194. Regeneron Pharmaceuticals
  195. RemeGen
  196. Roche
  197. Rockland Immunochemicals
  198. SafeBridge Consultants
  199. Samsung Medical Center
  200. Sanofi
  201. Seattle Genetics
  202. Seramun Diagnostica
  203. Servier
  204. Sesen Bio
  205. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  206. Shanghai Jiaolian Medicine Research and Development
  207. Shanghai Miracogen
  208. Shenogen Pharma
  209. Shire
  210. Siamab Therapeutics
  211. Skyline Ventures
  212. Sorrento Therapeutics
  213. SOTIO
  214. SouthernBiotech
  215. Sun Pharmaceutical Industries
  216. Sunomix Biosciences
  217. Surveyor Capital
  218. Sutro Biopharma
  219. SV Health Investors
  220. Swedish Orphan Biovitrum (Sobi)
  221. Synaffix
  222. Syngene International
  223. Synthon
  224. TaiMed Biologics
  225. Takeda Pharmaceutical
  226. TBD-Biodiscovery
  227. Teresi Pharmaceuticals
  228. Teva Pharmaceutical
  229. The Johns Hopkins University School of Medicine
  230. The University of Texas MD Anderson Cancer Center
  231. Theratechnologies
  232. Thermo Fisher Scientific
  233. ThioLogics
  234. TOT BIOPHARM
  235. Triphase Accelerator
  236. Tsuchikama Laboratory
  237. UCB
  238. Ultragenyx Pharmaceutical
  239. United Therapeutics
  240. UW Carbone Cancer Center
  241. Vaccinex
  242. Valeant Pharmaceuticals
  243. VelosBio
  244. Vida Ventures
  245. Visterra
  246. WuXi Biologics
  247. Wyeth
  248. Xintela
  249. Yale Cancer Center
  250. Y-Biologics
  251. Zhejiang Hisun Pharmaceutical
  252. Zymeworks

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com